ADMA Biologics (NASDAQ:ADMA) Trading Down 3.4% - Should You Sell?

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s share price dropped 3.4% during mid-day trading on Friday . The company traded as low as $21.01 and last traded at $21.08. Approximately 348,220 shares traded hands during trading, a decline of 90% from the average daily volume of 3,606,443 shares. The stock had previously closed at $21.83.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ADMA. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.

ADMA Biologics Trading Down 7.9 %

The firm has a market capitalization of $4.75 billion, a PE ratio of 71.82 and a beta of 0.64. The business has a fifty day moving average price of $19.08 and a two-hundred day moving average price of $15.35. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the firm posted $0.01 earnings per share. Analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The trade was a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ADMA. Hollencrest Capital Management purchased a new stake in ADMA Biologics during the 3rd quarter worth about $30,000. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics during the third quarter worth about $31,000. National Bank of Canada FI purchased a new stake in shares of ADMA Biologics during the third quarter worth approximately $35,000. Quest Partners LLC acquired a new stake in ADMA Biologics in the second quarter valued at approximately $29,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in ADMA Biologics in the third quarter worth approximately $62,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.